NAMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NewAmsterdam Pharma (NAMS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite short-term pre-market price decline and insider selling, the company's strong analyst ratings, upcoming catalysts like the PREVAIL trial update, and SwingMax signal make it a compelling long-term investment opportunity.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 59.369, and moving averages are converging, suggesting a potential breakout. Current price is near R1 resistance at 31.612, with support at 30.231.
Upcoming mid-year PREVAIL trial update and potential positive cardiovascular outcomes trial readout. SwingMax signal issued recently with a 3.40% price increase since the signal.
Insider selling has increased significantly by 113.69% over the last month. Revenue dropped significantly in the latest quarter, down -98.80% YoY.
In Q3 2025, revenue dropped to $348,000 (-98.80% YoY). However, net income improved to -$72,005,000 (+332.54% YoY), and EPS increased to -0.61 (+238.89% YoY). Gross margin remained stable at 100%.
Analysts are bullish with multiple Buy ratings and raised price targets. Truist initiated coverage with a $57 target, Guggenheim raised its target to $45, and RBC Capital raised its target to $47. Analysts cite confidence in the company's Phase 3 PREVAIL trial and potential for a major inflection point in 2027.
